沙利度胺联合MP方案治疗多发性骨髓瘤临床观察  

The Clinical Observation About Thalidomide+MP Treat Multipie Myeloma

作　　者：王璇[1] 尹颖[2] 张慧莹[1] 

机构地区：[1]吉林市北华大学附属医院血液科,吉林吉林132011 [2]吉林市红十字中心血站,吉林吉林132011

出　　处：《中国实用医药》2006年第3期63-,共1页China Practical Medicine

摘　　要：目的评价沙利度胺+MP治疗多发性骨髓瘤的效果。方法采用配对研究方法观察沙利度胺治疗多发性骨髓瘤19例的治疗效果,一组采用沙利度胺+MP,使用剂量:沙利度胺25mg/d口服d1～21+MP方案(马法兰10mg/㎡·d,口服共4天,泼尼松2mg/kg·d,口服共4天,共4周。)。另一组对照组只采用MP方案,方案同上。结果沙利度胺+MP治疗组有效率明显高于对照组。结论:沙利度胺+MP效果更好。Objective To evaluate the efficacy of Thalidomide+MP in the anaemia of multiple myeloma. Mothods Case-control study.One group received Thalidomide+MP, Thalidomide 25mg/d,p.o., d1～21.MP(Mel.10mg/㎡·d,p.o.,four days,Prep.2mg/kg·d,p.o.,four days ,for four weeks).the other group received MP,the method is alike.Result The increment of Thalidomide+MP was greater than in the control group.Conclusion Thalidomide+MP is more effective for the anaemia of multiple myeloma.

关 键 词：沙利度胺 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]